Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Leases (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Current Leases for 3 consecutive years, with $243000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Current Leases fell 3.19% year-over-year to $243000.0, compared with a TTM value of $243000.0 through Sep 2024, down 3.19%, and an annual FY2023 reading of $267000.0, up 8.1% over the prior year.
  • Current Leases was $243000.0 for Q3 2024 at Oramed Pharmaceuticals, down from $250000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $267000.0 in Q4 2023 and bottomed at $228000.0 in Q3 2022.
  • Average Current Leases over 3 years is $244363.6, with a median of $243000.0 recorded in 2024.
  • The sharpest move saw Current Leases increased 10.09% in 2023, then decreased 3.19% in 2024.
  • Year by year, Current Leases stood at $247000.0 in 2022, then rose by 8.1% to $267000.0 in 2023, then fell by 8.99% to $243000.0 in 2024.
  • Business Quant data shows Current Leases for ORMP at $243000.0 in Q3 2024, $250000.0 in Q2 2024, and $254000.0 in Q1 2024.